High frequency of promoter methylation of the 14-3-3 σ and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder

International Journal of Molecular Medicine

Volumn 20, Issue 4, 2007, Pages 557-563

  Kunze, Ekkehard ^a   Schlott, Thilo ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

14 3 3 ; Adenocarcinomas; CAGE 1; Caveolin 1; hDAB2IP; Promoter methylation; Signet ring cell carcinomas; SYK; Urinary bladder

Indexed keywords

CAGE1 PROTEIN, HUMAN; CAV1 PROTEIN, HUMAN; CAVEOLIN 1; EXONUCLEASE; NUCLEAR PROTEIN; SFN PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BLADDER; BLADDER TUMOR; DNA METHYLATION; GENETICS; HUMAN; METABOLISM; MUCOSA; POLYMERASE CHAIN REACTION; PROMOTER REGION; SIGNET RING CARCINOMA; TUMOR GENE;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CARCINOMA, SIGNET RING CELL; CAVEOLIN 1; DNA METHYLATION; EXONUCLEASES; GENES, NEOPLASM; HUMANS; MUCOUS MEMBRANE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 38449108628     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.4.557     Document Type: Article

References (54)

1. Mostofi FK: Potentialities of bladder epithelium. J Urol 71: 705-714, 1954.
2. Edwards PD, Hurm RA and Jaeschke WH: Conversion of cystitis glandulatis to adenocarcinoma. J Urol 108: 568-570, 1972.
3. Bullock PS, Thoni DE and Murphy WM: The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer 59: 2086-2090, 1987.
4. Kunze E: Formale Pathogenese des Harnblasenkarzinoms. In: Diagnostik und Therapie des Harnblasenkarzinoms. Bichler KH, Wilbert D, Wechsel HW and Strohmaier WS (eds). Einhorn- Presse Verlag, Reinbeck, pp14-42, 1998.
5. Kunze E: Histogenesis of nonurothelial carcinomas in the human and rat urinary bladder. Exp Toxicol Pathol 50: 341-355, 1998.
6. Kunze E and Francksen B: Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study. Urol Res 30: 66-78, 2002.
7. Kunze E, Francksen B and Schulz H: Expression of MUC5AC apomucin in transitional cell carcinomas of the urinary bladder and its possible role in the development of mucus-secreting adenocarcinomas. Virchows Arch 439: 609-615, 2001.
8. Kunze E, Krassenkova I and Fayyazi A: Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Histol Histopathol (In press).
9. Kunze E, von Bonin F, Werner C, Wendt M and Schlott T: Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med 17: 3-13, 2006.
10. Kunze E, Wendt M and Schlott T: Promoter hypermethylation of the 14-3-3 σ, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int J Mol Med 18: 547-557, 2006.
11. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14- 3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
12. Wang S, Ding YB, Chen GY, Xia JG and Wu ZY: Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J Gastroenterol 10: 1815-1818, 2004.
13. Cho B, Lee H, Jeong SW, Bang YJ, Lee HJ, Hwang KS, Kim HY, Lee YS, Kang GH and Jeong DI: Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in pre-malignant stage of gastric carcinoma. Biochem Biophys Res Commun 307: 52-63, 2003.
14. Chen T-F, Su T-H, Yeh K-T, Chang J-Y, Lin T-H, Chen J-C, Yuang S-S and Chang J-G: Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers. Int J Oncol 23: 599-604, 2003.
15. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh J-T, Gazdar AF and Shimizu N: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 10: 2082-2089, 2004.
16. Baylin SB, Herman JG, Graft JR, Vertino PM and Issa J-P: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
17. Ballestar E and Esteller M: The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23: 1103-1109, 2002.
18. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
19. Esteller M: Relevance of DNA methylation in the management ofcancer. Lancet Oncol 4: 351-358, 2003.
20. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-2-2 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
21. Leffers H, Madsen P, Rasmussen HH, Honoré B, Andersen AH, Walbum E, Vandekerckhove J and Celis JE: Molecular cloning and expression of the transformation sensitive epithelium marker stratifin. A member of a protein family that has been involved in the protein kinase C signalling pathway. J Mol Biol 231: 982-998, 1993. (Pubitemid 23209874)
22. Toyoshima F, Moriguchi T, Wada A, Fukuda M and Nishida E: Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J 17: 2728-2735, 1998.
23. Jin P, Hardy S and Morgan DO: Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141: 875-885, 1998.
24. Prasad GL, Valverius EM, McDuffie E and Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary calls. Cell Growth Differ 3: 507-513, 1992.
25. Dellambra E, Patrone M, Sparatore B, Negri A, Ceciliani F, Bondanza S, Molina F, Cancedda FD and de Luca M: Stratifin, a keratinocyte specific 14-3-3 protein, harbours a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci 108: 3569-3579, 1995.
26. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353, 2001.
27. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG island and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
28. Suzuki H, Itoh F, Toyota M, Kikucki T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
29. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B and Crook T: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16INK4a silencing and human papilloma virus negativity. Cancer Res 62: 2072-2076, 2002.
30. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N and Dahiya R: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316: 1156-1162, 2004. (Pubitemid 38369074)
31. Cho B, Lim Y, Lee DY, Park SY, Lee H, Kim WH, Yang H, Bang YJ and Yeoung DI: Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem Biophys Res Commun 292: 715-726, 2002. (Pubitemid 34681118)
32. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002.
33. Park S, Lim Y, Lee D, Cho B, Bang YJ, Sung S, Kim HY, Kim DK, Lee YS, Song YW and Yeoung DI: Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 1625: 173-182, 2003. (Pubitemid 36084487)
34. Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh H and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94: 1914-1918, 1977.
35. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N and Old LJ: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92: 856-860, 2001.
36. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H and Jaenisch R: Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492, 2003.
37. Eden A, Gaudet F, Waghmare A and Jaenisch R: Chromosomal instability and tumors promoted DNA hypomethylation. Science 300: 455, 2003.
38. Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC and Yakirevich E: Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 101: 190-195, 2002.
39. Razani B, Woodman SE and Lisanti MP: Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467, 2002.
40. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga H, Shichinohe T, Shinohara T, Itoh T, Kondo S and Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140-1144, 2002. (Pubitemid 35418110)
41. Campbell L, Gumbleton M and Griffiths DFR: Caveolin-1 over-expression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89: 1909-1913, 2003.
42. Yang G, Truong LD, Wheeler TM and Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
43. Ho C-C, Huang P-H, Huang H-Y, Chen Y-H, Yang P-C and Hsu S-M: Up-regulated cavolin-1 accentuates the metastasis capability of lung adenocarcinomas by inducing filopodia formation. Am J Pathol 161: 1647-1656, 2002.
44. Fine SW, Lisanti MP, Galbiati F and Li M: Elevated expression of caveolin-1 in adenocarcinomas of the colon. Am J Clin Pathol 115: 719-724, 2001. (Pubitemid 33051539)
45. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K and Miyauchi A: Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyreoid. Br J Cancer 86: 912-916, 2002. (Pubitemid 34271027)
46. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schäfer R and Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643, 2001.
47. Sada K, Takano T, Yanagi S and Yamamura H: Structure and function of SYK protein-tyrosine kinase. J Biochem 130: 177-186, 2001.
48. Yuan Y, Mendez R, Sahin A and Dai JL: Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 61: 5558-5561, 2001.
49. Xu X-X, Yi T, Tang B and Lambeth JD: Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 16: 1561-1569, 1998.
50. Zhou J and Hsieh J-T: The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. J Biol Chem 276: 27793-27798, 2001.
51. Yano M, Toyooka S, Tsukada K, Dote H, Ouchida M, Ave M, Hanabata T, Date H, Gazdar AF and Shimizu N: Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 113: 59-66, 2005. (Pubitemid 39507311)
52. Wang Z, Tseng C-P, Pong R-C, Chen H, McConnell JD, Navone N and Hsieh J-T: The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. J Biol Chem 277: 12622-12631, 2002.
53. Chen H, Pong R-C, Wang Z and Hsieh J-T: Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79: 573-581, 2002. (Pubitemid 34274299)
54. Fazili Z, Sun W, Mittelstaedt S, Cohen C and Xu X-X: Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 18: 3104-3113, 1999.